Article info
PDFClinical science
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema
- Correspondence to Dr Claus Zehetner, Department of Ophthalmology, Medical University Innsbruck, Anichstr. 35, Innsbruck 6020, Austria; claus.zehetner{at}i-med.ac.at
Citation
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema
Publication history
- Received August 4, 2012
- Revised November 29, 2012
- Accepted January 11, 2013
- First published February 5, 2013.
Online issue publication
March 22, 2016
Article Versions
- Previous version (22 March 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions